Synchron halts second-generation brain implant trial over performance problems
Synchron has paused enrollment in the multisite clinical trial of its newer, fully wireless Stentrode device after it failed to perform as expected in early participants. The Brooklyn-based brain-computer interface company says it voluntarily stopped enrollment after identifying a performance issue, and is simultaneously restructuring, cutting jobs and reducing its New York presence while expanding a San Diego team.
GoKawiil's interpretation of the reporting above, not reported fact.
The setback could slow Synchron's bid to compete with Neuralink and other brain-computer interface developers racing to bring wireless, minimally invasive implants to market. The restructuring and new device development suggest the company may be rethinking its engineering approach rather than simply tweaking the current design, though Synchron has not confirmed what specifically went wrong.
- Synchron paused its second-generation Stentrode trial after a performance issue in early participants
- The company is cutting jobs and shifting resources from New York to a new San Diego team
- Synchron's first-generation wired implant had already let volunteers control devices like iPads and Alexa with their thoughts
Source: wired.com — Emily Mullin, 2026-11-12
Published there as: “Synchron Pauses Trials of Its Brain Implant Due to Performance Issues”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.